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The number of reports of influenza-
vaccine–associated Guillain–Barré syndrome to the
national Vaccine Adverse Event Reporting System
increased from 37 in 1992–1993 to 74 in 1993–1994,





Patients given a diagnosis of the Guil-
lain–Barré syndrome in the 1992–1993 and 1993–1994
influenza-vaccination seasons were identified in the
hospital-discharge data bases of four states. Vacci-
nation histories were obtained by telephone inter-
views during 1995–1996 and were confirmed by the
vaccine providers. Disease with an onset within six
weeks after vaccination was defined as vaccine-
associated. Vaccine coverage in the population was





We interviewed 180 of 273 adults with the
Guillain–Barré syndrome; 15 declined to participate,
and the remaining 78 could not be contacted. The
vaccine providers confirmed influenza vaccination in
the six weeks before the onset of Guillain–Barré syn-
drome for 19 patients. The relative risk of the Guil-
lain–Barré syndrome associated with vaccination,
adjusted for age, sex, and vaccine season, was 1.7
(95 percent confidence interval, 1.0 to 2.8; P=0.04).
The adjusted relative risks were 2.0 for the 1992–1993
season (95 percent confidence interval, 1.0 to 4.3)
and 1.5 for the 1993–1994 season (95 percent confi-
dence interval, 0.8 to 2.9). In 9 of the 19 vaccine-
associated cases, the onset was in the second week




There was no increase in the risk of
vaccine-associated Guillain–Barré syndrome from
1992–1993 to 1993–1994. For the two seasons com-
bined, the adjusted relative risk of 1.7 suggests
slightly more than one additional case of Guillain–
Barré syndrome per million persons vaccinated
against influenza. (N Engl J Med 1998;339:1797-802.)
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UILLAIN–BARRÉ syndrome is charac-
terized by loss of reflexes and symmetric
paralysis, usually beginning in the legs,
with eventual nearly complete or com-




 It is mediated
by an immune response that results in the direct de-
struction of either the myelin sheath surrounding
the peripheral nerves or the axon itself, and it may





 Among the vaccines reported to be as-
sociated with the onset of Guillain–Barré syndrome
are the swine influenza (A/New Jersey) vaccine in





 The association with the A/New Jersey swine
influenza vaccine was notable for relative risks of
Guillain–Barré syndrome ranging from 4.0 to 7.6




Subsequent studies of Guillain–Barré syndrome and
influenza vaccines found low relative risks of 1.4 in
1978–1979, 0.6 to 1.4 in 1979–1980 and 1980–
1981, and 1.1 in 1980–1988; these relative risks





1990–1991 influenza season, an elevated risk was
found among vaccinated persons 18 to 64 years of
age (relative risk, 3.0; 95 percent confidence inter-





Reports of vaccine-associated Guillain–Barré syn-
drome are monitored by the Vaccine Adverse Event
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 An increase in the num-
ber of cases of Guillain–Barré syndrome after the re-
ceipt of influenza vaccine was reported to VAERS by
week 29 of the 1993–1994 influenza season. The
number increased from 21 in 1991–1992 to 37 in




Because reports to the VAERS consist only of data
on the number of vaccine-associated cases without
showing the number of people at risk, the CDC and
the University of Maryland School of Medicine
undertook a collaborative investigation to estimate
the relative risks associated with vaccination against





Data bases on hospital-discharge summaries were used to iden-
tify cases of Guillain–Barré syndrome in four states: Illinois,
Maryland, North Carolina, and Washington. Hospital charts of













 and with disease onset be-
tween September 1, 1992, and February 28, 1993, or between
September 1, 1993, and February 28, 1994, were reviewed by ab-
stractors who were unaware of the patients’ vaccination histories.
A standardized data-collection form based on widely accepted ab-





cedures for studies involving human subjects were followed, as re-
quired by the institutional review boards associated with the
University of Maryland at Baltimore, the CDC, and the partici-
pating states.
Cases were categorized as definite, probable, or possible, as not
Guillain–Barré syndrome (noncases), or as requiring review by a
neurologist. In definite cases, other conditions were ruled out
and the patients were afebrile on admission (unless they had fever
due to an illness other than Guillain–Barré syndrome) and had
symmetric, progressive paralysis in more than one limb, areflexia
or hyporeflexia in the legs and arms, a cerebrospinal fluid protein
level above 40 mg per deciliter with a mononuclear-cell count of
less than 10 per milliliter, and either died or reached the peak of
their neurologic illness within four weeks of onset. Patients meet-
ing all of these criteria who did not have a lumbar puncture, the
results of whose cerebrospinal fluid tests were missing, or whose
cerebrospinal fluid mononuclear-cell count was between 11 and
50 per milliliter were classified as probably having Guillain–Barré
syndrome. Patients with missing information for one or more of
the required criteria were classified as possibly having the syn-
drome. Patients whose charts provided definitive information that
they did not meet one or more of the required criteria were clas-
sified as not having the syndrome. If arm reflexes were normal or
information on arm reflexes was missing and if all other criteria
were met, the chart was reviewed by the study neurologist and
the illness was categorized as a case or noncase. Our algorithm
for categorizing cases as definite or probable was adapted from
published criteria used by expert neurologists to guide their re-
view of cases. The definite and probable cases differ only with re-
spect to the completeness of cerebrospinal fluid evaluation, which
is not a required criterion for diagnosis of Guillain–Barré syn-
drome. After implementing the computer algorithm, we found
that the completeness of cerebrospinal fluid evaluation was not
enough to distinguish definite from probable cases, and so we
combined the two groups.
Patients’ vaccination histories were collected by telephone in-
terviews. Providers were then contacted to obtain the exact dates
of vaccination. Vaccine-associated cases were defined a priori as
those with onset of Guillain–Barré syndrome within the six-week
period after influenza vaccination. Previous researchers used ei-
ther six- or eight-week periods after vaccination to define vaccine-
associated cases; however, the studies that reported an elevated
risk also showed that all or almost all of the risk was within the




The four study states had a total population of 21.2 million





 Rates of coverage with influenza vaccine for
the general population were obtained from a random-digit–dial-
ing telephone survey designed to determine whether respondents





 The survey instrument consisted of 49
items, including the following questions about influenza vaccina-
tions: “Did you get a flu shot during this past fall or winter —
that is, for the winter of 1993–1994?” “Approximately when did
you receive the flu vaccine shot during the winter of 1993–
1994?” Similar questions were asked for 1992–1993, as well as
questions about the vaccine provider, factors affecting the deci-
sion to be vaccinated, and indications for influenza vaccination. A
total of 1015 telephone interviews were conducted with adult res-
idents of the four study states, 19 percent of whom were 65 years
of age or older and 58 percent of whom were women. The survey
had an 81 percent response rate. A response-validation study of
the 1993–1994 data estimated that 90 percent of the positive
vaccination reports were correct for the vaccine season. The 1992–
1993 reports were validated by comparing the reported change





Ascertainment of cases (vaccine-associated and non–vaccine-
associated) and estimation of the population denominators (per-
son-weeks within the six-week period after vaccination and per-
son-weeks outside this period) were used to estimate the relative
risk of Guillain–Barré syndrome during the six weeks after influ-
enza vaccination. We used Poisson regression analysis to estimate
the effect of the vaccine on risk while controlling for age, vaccine
season, and sex. We controlled for age by including dummy var-
iables for the following age groups: 18 to 34, 35 to 44, 45 to 54,
55 to 64, 65 to 74, and 75 or more years. Standard Poisson re-
gression is based on the assumption that the amount of person-
time during which the population is exposed and the amount




 Reports of Vaccine-Associated Guillain–Barré Syn-
drome to the Vaccine Adverse Event Reporting System during


























THE GUILLAIN–BARRÉ SYNDROME AND THE 1992–1993 AND 1993–1994 INFLUENZA VACCINES
 






we only had estimates of the person-time exposed, because we
had to estimate the vaccine-coverage rates. To adjust our inferenc-
es to take this limitation into account, we used the method of




 This method was also
used to adjust for uncertainty in classifying six cases and resulted
in somewhat broader confidence intervals than would result from




We obtained hospital charts for 1109 of 1201 hos-
pital discharges (92 percent) with ICD-9 code 357.0
during the study periods, including 288 charts refer-
ring to multiple admissions. Of the 821 patients
whose charts we obtained, 62 (8 percent) resided
outside the study states, and another 153 (19 per-
cent) had onset of disease outside the study periods;
these patients were excluded from the study. The fi-
nal distribution of cases for the 606 remaining pa-
tients was as follows: 87 definite (14 percent), 211
probable (35 percent), 123 possible (20 percent),
and 185 noncases (31 percent). Of the 298 patients
with Guillain–Barré syndrome, 273 were 18 years of
age or older. In this group there were 37 definite and
81 probable cases in 1992–1993, as compared with
40 definite and 115 probable cases in 1993–1994.
The mean age of the 273 patients at admission
was 54 years (range, 18 to 90). The group was pre-
dominantly white (84 percent) and male (62 per-
cent). The mean cerebrospinal fluid protein level for
the patients was 128.9 mg per deciliter, and the
mean mononuclear-cell count was 1.6 per milliliter.
While they were hospitalized, 56 percent of patients
underwent plasmapheresis, and 22 percent received
ventilator support.
We interviewed 180 of the 273 patients (66 per-
cent) by telephone; 15 declined to participate, 58
could not be located, and the permission of the phy-
sician to interview the patient was not obtained for
20 patients. Of the 180 patient interviews, 141 (78
percent) were conducted directly with the patient
and 39 (22 percent) were conducted with spouses,
surviving children, parents, or other proxies. Al-
though the proportion of patients interviewed was
lower than we would have wished, the primary rea-
son that some patients were not interviewed was the
inability to locate them — a factor unlikely to be as-
sociated with vaccine history or recall of vaccina-
tions. In comparing interviewed with noninterviewed
patients, we found the two groups to be similar clin-
ically and slightly different demographically; the me-
dian age of the noninterviewed patients was 51
years, as compared with 56 years for the interviewed
patients (P=0.03).
Vaccine providers confirmed that 19 patients had
received influenza vaccine within six weeks before
the onset of Guillain–Barré syndrome. One hun-
dred forty-eight cases were categorized as non–
vaccine-associated (116 of the patients reported re-
ceiving no influenza vaccine, and 32 were vaccinated
outside the six-week period preceding the onset of
Guillain–Barré syndrome). Six patients who report-
ed receiving influenza vaccine did not give us per-
mission to contact their providers. Thus, we could
not confirm whether they were vaccinated within six
weeks before the onset of disease. Since it is likely
that a proportion of these cases were vaccine-asso-
ciated, excluding these patients would have intro-
duced bias into the analysis. To retain these cases in
the analysis, we used the approach of multiple impu-
tation. We based our multiple imputations on the
proportion of vaccine-associated cases among those
for which the date of vaccination could be con-
firmed. The approach appropriately inflates the con-
fidence intervals to adjust for the uncertainty about
the true status of the six cases. An additional seven
patients reported being vaccinated, but the vaccina-
tion could not be independently confirmed from the
provider’s records. All seven were excluded from
subsequent analysis. Two of these patients provided
credible accounts of influenza vaccinations that might
have occurred in the six weeks preceding the onset
of Guillain–Barré syndrome. Including these pa-
tients in the analysis (and categorizing two cases as
vaccine-associated) did not result in a changed point
estimate but did result in slightly narrower confi-
dence intervals (1.1 to 2.8).
The distribution of vaccine-associated cases ac-
cording to the date of onset of disease showed a
peak in the second week after vaccination (Fig. 2).
Of the 19 vaccine-associated cases, 9 had onset in
the second week after vaccination, all between day 9
and day 12. The probability of observing a distribu-
tion over the six weeks with at least this degree of
imbalance by chance alone was low (P=0.009, on
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ing to hospital charts, evidence of antecedent gastro-
intestinal illness, respiratory illness, Epstein–Barr vi-
rus infection, cytomegalovirus infection, or surgery
was less frequent for patients with vaccine-associated
Guillain–Barré syndrome than for patients with non–
vaccine-associated cases (33 percent vs. 57 percent,
P=0.06). The mean age of patients with vaccine-
associated Guillain–Barré syndrome was higher than
that of patients with the non–vaccine-associated cas-
es (66 vs. 55 years, P<0.001). The proportions of
patients who received mechanical ventilation (21
percent and 24 percent, respectively) and who died
in the hospital (6 percent and 4 percent, respective-
ly) were similar in the vaccine-associated and non–
vaccine-associated groups. Three of the 19 vaccine-
associated cases involved complete cerebrospinal flu-
id evaluation and were definite, and 13 involved in-
complete evaluation and were probable.
Vaccine coverage in the four study states increased
in all age groups between 1992–1993 and 1993–
1994, from 2.8 million to 3.6 million people 18 to
64 years of age and from 1.7 million to 2.1 million
people 65 years of age or older (Fig. 3). During the
two six-month study seasons, there were 61 million
person-weeks of exposure (when people were within
the six-week period after influenza vaccination) and
1048 million person-weeks of nonexposure (when
people were outside the six-week period after vacci-
nation, including person-weeks for those who were
not vaccinated at all, as well as person-weeks outside
the six-week exposure period for those who received
influenza vaccinations).
The overall relative risk of Guillain–Barré syn-
drome in the six weeks after influenza vaccination
was 2.4 (95 percent confidence interval, 1.5 to 3.8;
P<0.001) (Table 1). After adjustment for age group,
sex, and influenza season, the relative risk was 1.7
(95 percent confidence interval, 1.0 to 2.8; P=0.04).
(Preliminary estimates of a relative risk of 1.8 and a
95 percent confidence interval of 1.2 to 3.0 were
disseminated in influenza-vaccine package inserts for
1998–1999.) There was no significant difference in
the effect of vaccine between seasons (P=0.56),
broad age groups (P=0.71), or sexes (P=0.65). Point
estimates for the relative risks associated with vacci-
nation within 10-year age groups were as follows:
2.1 (95 percent confidence interval, 0.3 to 15.4) for
persons 45 to 54 years old, 2.2 (95 percent confi-
dence interval, 0.8 to 6.0) for those 55 to 64, 1.9
(95 percent confidence interval, 0.8 to 4.5) for those
65 to 74, and 1.8 (95 percent confidence interval,
0.7 to 4.9) for those 75 or older. No vaccine-associ-
ated cases were observed among the 4 million vac-
cine recipients who were under 45 years of age, re-




We estimate that after age, sex, and season have
been controlled for, the risk of the Guillain–Barré
syndrome is increased by a factor of 1.7 in the six
weeks after influenza vaccination. This is only slight-
ly higher than the relative risks reported in earlier
studies of influenza vaccine and Guillain–Barré syn-
drome, except for the much higher risks associated





variety of events are associated with the Guillain–




 and viral infections, the im-
munologic events leading to the Guillain–Barré syn-




We observed an average incidence of non–vaccine-
associated Guillain–Barré syndrome among adults
 















































































































All patients None 2.4 (1.5–3.8) <0.001
All patients Age group, season, sex 1.7 (1.0–2.8) 0.04
1992–1993 season Age group, sex 2.0 (1.0–4.3) 0.07
1993–1994 season Age group, sex 1.5 (0.8–2.9) 0.20
Age, 18–64 yr Season, sex 1.8 (1.0–3.5) 0.07
Age, »65 yr Season, sex 1.5 (0.7–3.3) 0.28
Male subjects Age group, season 1.9 (1.0–3.7) 0.07




 Influenza Vaccine Coverage in the Four Study States
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of 0.145 case per million persons per week, or a back-
ground incidence of 0.87 case per million persons
per six-week period. The age-, sex-, and season-
adjusted relative risk in the six-week period after
vaccination was 1.7. Thus, the calculated risk attrib-
utable to the vaccine in the six-week period after
vaccination was 0.61 case per million vaccinations.
This estimate of the vaccine-attributable risk is con-
servative because of four factors: we received 92 per-
cent of hospital charts, we did not include patients
hospitalized out of state, our base-line rate did not
include patients who were not interviewed, and our
base-line rate did not include those with possible
cases of Guillain–Barré syndrome. After adjustment
for the first three factors, the best estimate of the
attributable risk would be 1.1 cases per million vac-
cinations. Thus, the adjusted relative risk of 1.7 sug-
gests that just over one additional case of Guillain–
Barré syndrome occurred per million vaccinations.
Adjusting for all four factors would increase the best
estimate of attributable risk to a maximum (if all were
definite cases) of 1.6 cases per million vaccinations.
The distribution of times of onset after vaccina-
tion showed a peak in the second week, suggesting
a relation between vaccination and the onset of dis-
ease. These findings differ from the finding that the
swine influenza vaccine was associated with a peak
of cases in the second and third weeks after vaccina-




However, Winer and colleagues, in discussing the
onset of Guillain–Barré syndrome after respiratory
infections (another possible trigger), noted that the
greatest relative risk of Guillain–Barré syndrome was





though the differences were not significant, the low-
er percentage of other antecedent events recorded in
the hospital charts of patients with vaccine-associat-
ed cases as compared with other patients is also con-
sistent with the hypothesis that influenza vaccine




An increase in reports to the VAERS may be due
to an increase in the efficiency of reporting, vaccine
coverage, the background rate of an illness or event,
or the risk associated with a vaccine. Only the last





 Our study suggests that the increase
in reports of vaccine-associated Guillain–Barré syn-
drome in 1993–1994 was probably due to an in-
crease in both influenza vaccine coverage and the
base-line incidence of Guillain–Barré syndrome, but
not to an increase in vaccine-specific risk. The ab-
sence of major publicity about vaccine-associated
Guillain–Barré syndrome during the study period
argues against changes in reporting efficiency as an
explanation of changes in the number of reports.
This study highlights the difficulty of relying on pas-
sive surveillance (such as VAERS) alone for identify-




In February 1997, preliminary findings of this
study were presented to the Advisory Committee on
Immunization Practices of the U.S. Public Health
Service for use in developing their recommendations
on the prevention and control of influenza, and re-







Among persons who received the swine influenza vaccine
in 1976, the rate of Guillain–Barré syndrome that exceed-
ed the background rate was slightly less than 10 cases per
million vaccinated. Even if Guillain–Barré syndrome were
a true side effect in subsequent years, the estimated risk
for Guillain–Barré syndrome of 1 to 2 cases per million
persons vaccinated is substantially less than that for severe
influenza, which could be prevented by vaccination in all
age groups, especially persons aged »65 years and those
who have medical indications for influenza vaccination.
. . . During influenza epidemics from 1969–70 through
1993–94, the estimated number of influenza-associated
hospitalizations has ranged from approximately 20,000 to
>300,000 per epidemic with an average of approximate-
ly 130,000 to 170,000 per epidemic. . . . An estimated
>20,000 influenza-associated deaths occurred during each
of 11 different U.S. epidemics from 1972–73 through
1994–95, and 40,000 influenza-associated deaths oc-




Our data, therefore, do not suggest an increased
risk associated with the influenza vaccine of 1993–
1994 as compared with 1992–1993, as was first sug-
gested by the increase in cases reported to the
VAERS. Rather, our findings support the hypothesis
that a small risk of Guillain–Barré syndrome was as-
sociated with the influenza vaccines in both 1992–
1993 and 1993–1994.
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